StockData
Benitec Biopharma Inc. logo

Benitec Biopharma Inc. (BNTC) company profile

BNTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/30
$9.04−0.05 (-0.55%)

Close on Nov 13, 2026Market cap $315.34MP/E –Yield –

About Benitec Biopharma

Pharmaceutical Preparations, SIC 2834

Benitec Biopharma Inc. is a clinical-stage biotechnology company that develops genetic medicines. The company utilizes a therapeutic platform combining gene silencing with functional gene replacement delivered through viral vectors. Its primary product candidate is BB-301, an investigational gene therapy designed to treat oculopharyngeal muscular dystrophy, a chronic degenerative muscle disorder. The company aims to serve patients suffering from this condition. Additionally, it engages with larger biopharmaceutical firms as commercial partners through potential co-development collaborations and out-licensing agreements.

Benitec is headquartered in Hayward, California. The company does not own or operate manufacturing facilities, instead planning to use contract manufacturing organizations. Its clinical programs address a disease diagnosed in approximately 35 countries worldwide. In addition, the organization maintains active patent families and holds registered trademarks across international jurisdictions, including the United States, Australia, the United Kingdom, and the European Union.

Summary of the business section of Benitec Biopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Benitec Biopharma Inc.
Founded
1995
Headquarters
Hayward, CA
Address
3940 Trust Way 94545
Phone
(510) 780-0819
Employees
24, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, San Diego, California

Stock & identifiers

Ticker
BNTC
Exchange
Nasdaq
IPO date
Oct 6, 2020
Shares outstanding
35M, Sep 4, 2026
Public float
$143.06M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
9-for-2, May 14, 2025; 1-for-17 reverse, Jul 26, 2023; 1-for-1.5 reverse, Apr 15, 2020; 1-for-10 reverse, Nov 18, 2019; 1-for-4 reverse, Jun 16, 2015
SEC CIK
1808898
CUSIP
08205P209
ISIN
US08205P2092
FIGI
BBG00R712L56
Share class FIGI
BBG00R712L65
LEI
5493001KMFMXZM1EU014
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Megan BostonChief Financial Officer, Director25,927
Jerel A. BanksChief Executive Officer, Director–
Sophie MukadamChief Operating Officer6,016
J. Kevin BuchiDirector155,723
David Matthew FriedmanDirector–
Sharon MatesDirector–
Aaron CowenDirector1,848,156
Montanova Capital, LlcDirector9,538,175
Averill Master Fund, Ltd.Director7,920,175
Kishan MehtaDirector–
Edward F. SmithDirector0
Peter FrancisDirector5,038

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$6.52M$9.54M$4.94M$330–
FY2025$25.87M$26.72M$6.19M$289–
FY2024$3.16M$4.29M$1.44M$172–
FY2023$918.73K$701.87K$469.46K$-79–
FY2022$799.96K-$176.70K$456.48K$-71–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Dr. Jerel Banks, M.D. Ph.D
Chairman and Chief Executive Officer
$667.00K$550.28K$5.25M$46.64K$6.52M-75%
Megan Boston
Chief Financial Officer, Secretary
$531.90K$281.38K$2.33M$19.76K$3.17M-63%
Sophie Mukadam
Chief Operating Officer
$500.00K$300.00K$5.84M$70.44K$6.71M+78%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 6, 2020
Offer price
$3.10
Securities offered
2,666,644
Gross proceeds
$8.27M
Exchange
Nasdaq
Lock-up ends (est.)
Apr 4, 2021

“Per Share of Common Stock Per Pre-Funded Warrant Total Public offering price $ 3.10 $ 3.09 $ 9,994,406.98 Underwriting discounts and commissions(1) $ 0.248 $ 0.248 $ 799,999.89 Proceeds to us (before expenses) $ 2.852 $ 2.842 $ 9,194,407.09 (1) We have agreed to reimburse certain expenses of the underwriter, including a management fee equal to 1% of the”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we had 24 full-time employees, one of whom has an MD, PhD, eight have a PhD, four have a Master’s Degree, two have a biotechnology certificate, and one has an MBA, for a total of 13 with post-graduate degrees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?